Recipharm, a Swedish contract development and manufacturing organization, and LIDDS, a developer of pharmaceutical products for cancer and other diseases, have together set up a manufacturing line for LIDDS’ prostate cancer drug, Liproca Depot, at Recipharm’s facility in Solna, Sweden.

The manufacturing line is dedicated to the first product based on LIDDS’ NanoZolid technology, which allows fo controlled, sustained and customized release of medication for up to six months. Clinical trial material has already been produced, and the facility is ready for future commercial manufacturing of Liproca Depot or other pharmaceutical formulations based on the NanoZolid technology. The manufacturing line has been adapted for GMP production and is industrialized according to a process invented by LIDDS.

In December 2015, the companies signed an exclusive collaboration agreement regarding scale-up of the production process and commercial manufacture of Liproca Depot. In connection with the agreement, Recipharm invested SEK 5 million ($587,730) in a private placement, thus becoming the third largest shareholder of LIDDS.

Source: Recipharm